SE9802438D0 - Läkemedel för behandling av tvångstanke-tvångshandlingssjukdom - Google Patents

Läkemedel för behandling av tvångstanke-tvångshandlingssjukdom

Info

Publication number
SE9802438D0
SE9802438D0 SE9802438A SE9802438A SE9802438D0 SE 9802438 D0 SE9802438 D0 SE 9802438D0 SE 9802438 A SE9802438 A SE 9802438A SE 9802438 A SE9802438 A SE 9802438A SE 9802438 D0 SE9802438 D0 SE 9802438D0
Authority
SE
Sweden
Prior art keywords
treatment
obsessive
compulsive disorder
drugs
ocd
Prior art date
Application number
SE9802438A
Other languages
English (en)
Other versions
SE511005C2 (sv
SE9802438L (sv
Inventor
Tomas Eriksson
Original Assignee
Laekartjaenster I Vaestsverige
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekartjaenster I Vaestsverige filed Critical Laekartjaenster I Vaestsverige
Priority to SE9802438A priority Critical patent/SE9802438L/sv
Publication of SE9802438D0 publication Critical patent/SE9802438D0/sv
Priority to EP99933439A priority patent/EP1094830B1/en
Priority to JP2000557849A priority patent/JP2002519386A/ja
Priority to DE69927376T priority patent/DE69927376D1/de
Priority to CA002336656A priority patent/CA2336656A1/en
Priority to PCT/SE1999/001218 priority patent/WO2000001403A1/en
Priority to AU49494/99A priority patent/AU4949499A/en
Priority to AT99933439T priority patent/ATE304862T1/de
Publication of SE511005C2 publication Critical patent/SE511005C2/sv
Publication of SE9802438L publication Critical patent/SE9802438L/sv
Priority to US10/463,568 priority patent/US20030216293A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9802438A 1998-07-07 1998-07-07 Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom SE9802438L (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9802438A SE9802438L (sv) 1998-07-07 1998-07-07 Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
AT99933439T ATE304862T1 (de) 1998-07-07 1999-07-05 Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
CA002336656A CA2336656A1 (en) 1998-07-07 1999-07-05 Use of composition comprising at least one substance within the group gnrh-analogues for treatment of obsessive-compulsive disorder (ocd)
JP2000557849A JP2002519386A (ja) 1998-07-07 1999-07-05 強迫性障害（ＯＣＤ）の治療を目的とするＧｎＲＨ−類似体群の中の少なくとも一種類の物質を含む組成物を使用した治療薬
DE69927376T DE69927376D1 (de) 1998-07-07 1999-07-05 Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
EP99933439A EP1094830B1 (en) 1998-07-07 1999-07-05 USE OF COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WITHIN THE GROUP GnRH-ANALOGUES FOR TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
PCT/SE1999/001218 WO2000001403A1 (en) 1998-07-07 1999-07-05 USE OF COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WITHIN THE GROUP GnRH-ANALOGUES FOR TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
AU49494/99A AU4949499A (en) 1998-07-07 1999-07-05 Use of composition comprising at least one substance within the group gnrh-analogues for treatment of obsessive-compulsive disorder (ocd)
US10/463,568 US20030216293A1 (en) 1998-07-07 2003-06-17 Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive -compulsive disorder (OCD)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802438A SE9802438L (sv) 1998-07-07 1998-07-07 Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom

Publications (3)

Publication Number Publication Date
SE9802438D0 true SE9802438D0 (sv) 1998-07-07
SE511005C2 SE511005C2 (sv) 1999-07-19
SE9802438L SE9802438L (sv) 1999-07-19

Family

ID=20411995

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802438A SE9802438L (sv) 1998-07-07 1998-07-07 Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom

Country Status (8)

Country Link
EP (1) EP1094830B1 (sv)
JP (1) JP2002519386A (sv)
AT (1) ATE304862T1 (sv)
AU (1) AU4949499A (sv)
CA (1) CA2336656A1 (sv)
DE (1) DE69927376D1 (sv)
SE (1) SE9802438L (sv)
WO (1) WO2000001403A1 (sv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147138A0 (en) 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE514606C2 (sv) * 1998-08-26 2001-03-19 Laekartjaenster I Vaestsverige Läkemedel innehållande GnRH-analoger för behandling av schizofreni

Also Published As

Publication number Publication date
SE511005C2 (sv) 1999-07-19
WO2000001403A1 (en) 2000-01-13
JP2002519386A (ja) 2002-07-02
SE9802438L (sv) 1999-07-19
EP1094830A1 (en) 2001-05-02
DE69927376D1 (de) 2006-02-02
CA2336656A1 (en) 2000-01-13
ATE304862T1 (de) 2005-10-15
AU4949499A (en) 2000-01-24
EP1094830B1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
EA200000814A1 (ru) Фармацевтическая композиция топирамата
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
TR200001795T2 (tr) 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı.
MXPA03007712A (es) Sales farmaceuticas.
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
WO2004043341A3 (en) Treatment for hemorrhagic shock
PT1176963E (pt) Utilizacao de ligandos do receptor d3 da dopamina no fabrico de medicamentos para o tratamento de disturbios da funcao renal
UA88941C2 (ru) Замещенные 4-фенилтетрагидроизохинолины, их применение как лекарственных средств, а также лекарственные средства, которые их содержат
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
DK0846173T3 (da) Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
WO2005048927A3 (en) Methods and reagents for the treatment of inflammatory disorders
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
SE9802438D0 (sv) Läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
SE9802836D0 (sv) Läkemedel för behandling av schizofreni
MXPA05010707A (es) Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.

Legal Events

Date Code Title Description
NUG Patent has lapsed